Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sequential therapy with caspofungin and fluconazole for Candida albicans infection.

Literature DB >> 15388480

Sequential therapy with caspofungin and fluconazole for Candida albicans infection.

Francesco Barchiesi¹, Elisabetta Spreghini, Isabella Baldassarri, Anna Marigliano, Daniela Arzeni, Daniele Giannini, Giorgio Scalise.

Abstract

A sequential therapy of caspofungin (CAS) and fluconazole (FLC) administration for treatment of Candida albicans infection was investigated. Treatment with CAS followed by FLC was as effective as CAS treatment given alone for the same duration. Our data suggest that switching from CAS to FLC is a potentially explorable therapeutic option for treatment of systemic candidiasis.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2004 PMID： 15388480 PMCID： PMC521911 DOI： 10.1128/AAC.48.10.4056-4058.2004

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

Review 1. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.

Authors: Dimitrios P Kontoyiannis; Russell E Lewis
Journal: Drug Resist Updat Date: 2003-10 Impact factor: 18.500

2. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Authors: Sevtap Arikan; Mario Lozano-Chiu; Victor Paetznick; John H Rex
Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191

3. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.

Authors: J A Vazquez; M Lynch; D Boikov; J D Sobel
Journal: Antimicrob Agents Chemother Date: 1997-07 Impact factor: 5.191

4. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.

Authors: Stefano P Bachmann; Thomas F Patterson; José L López-Ribot
Journal: J Clin Microbiol Date: 2002-06 Impact factor: 5.948

5. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

Authors: M A Pfaller; R N Jones; G V Doern; A C Fluit; J Verhoef; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal: Diagn Microbiol Infect Dis Date: 1999-09 Impact factor: 2.803

6. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors: M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal: Antimicrob Agents Chemother Date: 2003-03 Impact factor: 5.191

Sequential therapy with caspofungin and fluconazole for Candida albicans infection.

Review 1. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.

2. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

3. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.

4. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.

5. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

6. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

7. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Review 8. Oral azole drugs as systemic antifungal therapy.

9. Comparison of caspofungin and amphotericin B for invasive candidiasis.

10. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

1. Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.

Review 2. A Bright Future for Fluorescence Imaging of Fungi in Living Hosts.